TR200103271T2 - Anti-inflammatory therapy for infection that occurs through inflammation. - Google Patents

Anti-inflammatory therapy for infection that occurs through inflammation.

Info

Publication number
TR200103271T2
TR200103271T2 TR2001/03271T TR200103271T TR200103271T2 TR 200103271 T2 TR200103271 T2 TR 200103271T2 TR 2001/03271 T TR2001/03271 T TR 2001/03271T TR 200103271 T TR200103271 T TR 200103271T TR 200103271 T2 TR200103271 T2 TR 200103271T2
Authority
TR
Turkey
Prior art keywords
inflammation
infection
occurs
inflammatory therapy
progression
Prior art date
Application number
TR2001/03271T
Other languages
Turkish (tr)
Inventor
A. Anton Peter
A. Poles Michael
V. Giorgi Janis (Vefat Etm��T�R)
E. Elliott Julie
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Publication of TR200103271T2 publication Critical patent/TR200103271T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2066—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Abstract

Bu bulus ile, inflamasyon araciligiyla gerçeklesen bir mukozal infeksiyonun ilerlemesini inhibe etmek için yöntemler saglanmistir. Söz konusu yöntemler, bir anti-inflamatuar maddeden etkili bir miktari hastaya vermekten meydana gelir. Bu bulus ile ayrica, bir mukozal infeksiyonun aktivasyonunu ve ilerlemesini önlemek ve inhibe etmek için kompozisyonlar ve üretim araçlari saglanir.With this invention, methods are provided to inhibit the progression of a mucosal infection by inflammation. These methods consist in delivering an effective amount of an anti-inflammatory agent to the patient. In addition, this invention provides compositions and means of production to prevent and inhibit the activation and progression of a mucosal infection.

TR2001/03271T 1999-05-14 2000-05-12 Anti-inflammatory therapy for infection that occurs through inflammation. TR200103271T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13409199P 1999-05-14 1999-05-14

Publications (1)

Publication Number Publication Date
TR200103271T2 true TR200103271T2 (en) 2002-06-21

Family

ID=22461735

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/03271T TR200103271T2 (en) 1999-05-14 2000-05-12 Anti-inflammatory therapy for infection that occurs through inflammation.

Country Status (13)

Country Link
EP (1) EP1202620A1 (en)
JP (1) JP2002544210A (en)
KR (1) KR20020024587A (en)
CN (1) CN1353573A (en)
AU (1) AU5010800A (en)
BR (1) BR0010546A (en)
CA (1) CA2368593A1 (en)
HK (1) HK1047216A1 (en)
IL (1) IL146130A0 (en)
MX (1) MXPA01011606A (en)
PL (1) PL351710A1 (en)
TR (1) TR200103271T2 (en)
WO (1) WO2000069255A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7090201A (en) * 2000-07-20 2002-02-05 Lauras As Method
AU2003201811A1 (en) * 2002-01-10 2003-07-30 Pharmacia & Upjohn Company Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections
AR039540A1 (en) * 2002-05-13 2005-02-23 Tibotec Pharm Ltd MICROBICIDE COMPOUNDS WITH PIRIMIDINE OR TRIAZINE CONTENT
US6790867B2 (en) * 2002-05-20 2004-09-14 Schering-Plough Animal Health Corporation Compositions and method for treating infection in cattle and swine
CA2866848C (en) 2002-07-30 2017-01-03 Omeros Corporation Ophthalmologic irrigation solutions and method
ITMI20031311A1 (en) * 2003-06-27 2004-12-28 Indena Spa FORMULATIONS FOR THE TREATMENT OF ARTHROSIC DISORDERS.
SG148198A1 (en) * 2003-11-21 2008-12-31 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
CN102002476B (en) * 2010-08-20 2013-05-08 上海市公共卫生临床中心 Human mucous membrane living tissue model cultured in vitro as well as building method and application thereof
CN102557976B (en) * 2010-12-15 2015-06-10 辽宁盛京制药有限公司 Bromfenac organic salt, and preparation method thereof, composition thereof and application thereof
EP2481751A1 (en) * 2011-01-26 2012-08-01 PharmaSurgics in Sweden AB Human lactoferrin derived peptides
AU2013201465B2 (en) 2012-10-24 2016-03-03 Rayner Surgical (Ireland) Limited Stable preservative-free mydriatic and anti-inflammatory solutions for injection
CN104013959A (en) * 2014-05-21 2014-09-03 郭和友 Reverse transcription inhibitor, immunity and antibody cell three-combined therapy
CN105456273A (en) * 2014-09-02 2016-04-06 杭州雷索药业有限公司 Application of nevirapine in preparing anti-inflammatory medicine
TWI809304B (en) 2014-12-01 2023-07-21 奥默羅斯公司 Anti-inflammatory and mydriatic intracameral solutions for inhibition of postoperative ocular inflammatory conditions
CN106309445A (en) * 2016-08-18 2017-01-11 滨州医学院 New medical application of Nelfinavir to enhancement of anti-inflammatory action of glucocorticoid
CN106176751A (en) * 2016-08-18 2016-12-07 滨州医学院 Indinavir strengthens the new medical use of glucocorticoid antiinflammatory action
CN106176739A (en) * 2016-08-18 2016-12-07 滨州医学院 Ritonavir strengthens the new medical use of glucocorticoid antiinflammatory action

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605885A (en) * 1988-05-05 1997-02-25 Entremed, Inc. Method for stimulating the immune system
EP0407701A3 (en) * 1989-05-15 1992-04-22 Fujisawa Pharmaceutical Co., Ltd. Antiretroviral pyrroline and pyrrolidine sulfonic acid derivatives
US5891924A (en) * 1996-09-26 1999-04-06 Research Development Foundation Curcumin (diferuloylmethane) inhibition of NFκB activation

Also Published As

Publication number Publication date
CA2368593A1 (en) 2000-11-23
PL351710A1 (en) 2003-06-02
IL146130A0 (en) 2002-07-25
KR20020024587A (en) 2002-03-30
WO2000069255A1 (en) 2000-11-23
JP2002544210A (en) 2002-12-24
WO2000069255A8 (en) 2001-03-22
MXPA01011606A (en) 2003-09-10
BR0010546A (en) 2002-03-05
AU5010800A (en) 2000-12-05
CN1353573A (en) 2002-06-12
HK1047216A1 (en) 2003-02-14
EP1202620A1 (en) 2002-05-08

Similar Documents

Publication Publication Date Title
TR200103271T2 (en) Anti-inflammatory therapy for infection that occurs through inflammation.
TR200101895T2 (en) Treatment of sexual ailments.
TR200200118T2 (en) New combinations
ECSP034568A (en) PIRIMIDIN 2,4,6-TRIONA TYPE METALOPROTEINASE INHIBITORS
ATE336229T1 (en) COMPOSITION BASED ON POLYMERIC MICELLARS
CO4340688A1 (en) QUINAZOLINE DERIVATIVES AND PROCEDURES FOR THE USE OF THE SAME, AS AGENTS AGAINST CANCER, IN MAMMALS.
HN2001000244A (en) SPIROPIRIMIDIN INHIBITORS - 2, 4, 6 - TRIONA METALOPROTEINASAS.
EA200500149A1 (en) Tissue Protective Cytokines for the Protection, Restoration and Stimulation of Reactive Cells, Tissues and Organs
CY1108532T1 (en) UNIONS AND COMPOSITIONS FOR PROVIDING ACTIVE AGENTS
DE60038183D1 (en) COMPOUNDS AND COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS
TR201900542T4 (en) Compositions for treating pain and / or inflammation.
SE0300971D0 (en) Nitric oxide in the treatment of inflammation
CY1106595T1 (en) PEGMA COMPOSITION AND INTRASCORAL ADMINISTRATION OF A COMPOSITION FOR THE THERAPEUTIC TREATMENT OF HYPOGONADISM
ATE413179T1 (en) THERAPEUTIC USES OF STEROIDS IN BLOOD CELL DEFICIENCY CONDITIONS
TR200101719T2 (en) The use of apomorphine in drug manufacture for the treatment of organic erectile dysfunction in men
TR200201089T2 (en) Treatment of microcirculatory disorders due to fibrin of dipyridamole or mopidamol
TR200102107T2 (en) Tumor necrosis factor antagonists and their use in endometriosis.
TR200201071T2 (en) Emphysema treatment using Rar selective retinoid antagonists
DE60228544D1 (en) TRIPTOLID PRODRUGS FOR CANCER THERAPY
IS6130A (en) Anti-inflammatory treatment for inflammation associated with infection
TR200101722T2 (en) Combination of serivastatin and fibrates.
NO20015338D0 (en) Androgen derivatives and their use
DK1150704T3 (en) Melagatran for the treatment of inflammation
WO2003106640A3 (en) Cell targeting methods and compositions
SE9802209D0 (en) Novel compounds